MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

RXi Pharmaceuticals Corp Company Profile (NASDAQ:RXII)

Consensus Ratings for RXi Pharmaceuticals Corp (NASDAQ:RXII) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.50 (20.69% upside)

Analysts' Ratings History for RXi Pharmaceuticals Corp (NASDAQ:RXII)
Show:
DateFirmActionRatingPrice TargetActions
6/7/2016HC WainwrightInitiated CoverageBuy$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for RXi Pharmaceuticals Corp (NASDAQ:RXII)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/13/2016Q116($0.45)($0.34)$34.00 million$10.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2016Q415($0.05)($0.04)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.04)($0.04)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.09)($0.05)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q115($0.10)($0.13)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2015Q414($0.14)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q314($0.22)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($0.25)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q114($0.31)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/28/2014($0.31)$0.84ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2012Q312($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for RXi Pharmaceuticals Corp (NASDAQ:RXII)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)
Dividend History for RXi Pharmaceuticals Corp (NASDAQ:RXII)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for RXi Pharmaceuticals Corp (NASDAQ:RXII)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/2/2015Geert CauwenberghCEOBuy5,000$0.72$3,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Geert CauwenberghCEOBuy4,000$1.17$4,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2015Geert CauwenberghCEOBuy2,000$1.24$2,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2015Robert J BittermanDirectorBuy5,000$1.20$6,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Geert CauwenberghCEOBuy10,000$1.03$10,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2014Geert CauwenberghCEOBuy2,500$1.59$3,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2014Geert CauwenberghCEOBuy3,000$1.68$5,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2014Geert CauwenberghCEOBuy4,500$2.20$9,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Geert CauwenberghCEOBuy5,000$2.08$10,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Geert CauwenberghCEOBuy10,000$2.18$21,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2014Geert CauwenberghCEOBuy1,000$2.50$2,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2014Geert CauwenberghCEOBuy1,400$2.57$3,598.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2014Geert CauwenberghCEOBuy2,000$2.86$5,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2014Geert CauwenberghCEOBuy2,000$2.98$5,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Geert CauwenberghCEOBuy1,000$3.05$3,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Geert CauwenberghCEOBuy2,000$2.94$5,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/31/2013Geert CauwenberghCEOBuy1,000$3.17$3,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2013Geert CauwenberghCEOBuy1,000$3.34$3,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2013Geert CauwenberghCEOBuy1,000$3.15$3,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2013Curtis LockshinDirectorBuy1,000$3.70$3,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for RXi Pharmaceuticals Corp (NASDAQ:RXII)
DateHeadline
06/24/16 06:19 PMShare Volatility Check for: RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Press Telegraph
06/21/16 10:34 AMStrong Buy Calls Count For RXI Pharmaceuticals Corporation (NASDAQ:RXII) At 2 - Investor Newswire
06/21/16 10:34 AMThis Weeks Broker Views For RXI Pharmaceuticals Corporation (RXII) - Fiscal Standard
06/13/16 09:11 AMTrend Of Rating Given To RXI Pharmaceuticals Corporation (NASDAQ:RXII) - Investor Newswire
06/06/16 11:11 AMRXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
05/31/16 06:19 AMNext Weeks Broker Price Targets For RXI Pharmaceuticals Corporation (RXII) - Share Trading News - Next Weeks Broker Price Targets For RXI Pharmaceuticals Corporation (RXII)Share Trading NewsRXI Pharmaceuticals Corporation has a 50 day moving average of 2.25 and a 200 day moving average of 3.04. The stock's market capitalization is 14.18M, it has a 52-week low of 1.26 and a 52-week high of 6.49. The share price of the company (RXII) was up ...Rxi Pharmaceuticals Corporation (NASDAQ:RXII) Sellers Increased By 13.42% Their ShortsHNNall 4 news articles »
05/30/16 07:05 AMRxi Pharmaceuticals Corporation (NASDAQ:RXII) Sellers Increased By 13.42% Their Shorts - HNN - Rxi Pharmaceuticals Corporation (NASDAQ:RXII) Sellers Increased By 13.42% Their ShortsHNNThe stock of Rxi Pharmaceuticals Corporation (NASDAQ:RXII) registered an increase of 13.42% in short interest. RXII's total short interest was 153,000 shares in May as published by FINRA. Its up 13.42% from 134,900 shares, reported previously.
05/27/16 09:19 PMRXI Pharmaceuticals Corporation (NASDAQ:RXII) Closes At $2.17 - Investor Newswire - RXI Pharmaceuticals Corporation (NASDAQ:RXII) Closes At $2.17Investor NewswireYesterday, the stock of RXI Pharmaceuticals Corporation (NASDAQ:RXII) closed at $2.17 after opening at $2.16 and registering high of $2.21 and low of $2.16. The last price is $-4.28 off 1-year high of $6.49 and $0.95 away from low of $1.26 during same ...and more »
05/26/16 07:04 AMRxi Pharmaceuticals Corporation (NASDAQ:RXII) Shorts Decreased by 21.16% After Short Covering - Wall Street Hints and News - Rxi Pharmaceuticals Corporation (NASDAQ:RXII) Shorts Decreased by 21.16% After Short CoveringWall Street Hints and NewsThe stock of Rxi Pharmaceuticals Corporation (NASDAQ:RXII) registered a decrease of 21.16% in short interest. RXII's total short interest was 134,900 shares in May as published by FINRA. Its down 21.16% from 171,100 shares, reported previously.
05/23/16 08:43 AMPreview of HC Stock's Movement: Immunomedics, Inc. (NASDAQ:IMMU), RXi Pharmaceuticals Corp (NASDAQ:RXII) - share market updates (press release) - share market updates (press release)Preview of HC Stock's Movement: Immunomedics, Inc. (NASDAQ:IMMU), RXi Pharmaceuticals Corp (NASDAQ:RXII)share market updates (press release)Shares of Immunomedics, Inc. (NASDAQ:IMMU) ended Friday session in red amid volatile trading. The shares closed down -0.03 points or -0.72% at $4.14 with 1.86 million shares getting traded. Post opening the session at $4.20, the shares hit an intraday ...and more »
05/22/16 08:34 PMAfter Last Week What Do Analysts Think Of RXI Pharmaceuticals Corporation (RXII) - Share Trading News - After Last Week What Do Analysts Think Of RXI Pharmaceuticals Corporation (RXII)Share Trading NewsThe share price of RXI Pharmaceuticals Corporation (RXII) was down -3.04% during the last trading session, with a day high of 2.39. 40815 shares were traded on RXI Pharmaceuticals Corporation's last session. The stock's 50 day moving average is 2.31 ...
05/20/16 08:58 PMRevenue Update on RXi Pharmaceuticals Corp(NASDAQ:RXII) - Trade Calls - Revenue Update on RXi Pharmaceuticals Corp(NASDAQ:RXII)Trade CallsRXi Pharmaceuticals Corp(NASDAQ:RXII) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 12, 2016. Earnings per share were $-0.34. Analysts had estimated an EPS of $-0.45. RXi Pharmaceuticals ...RXI Pharmaceuticals Corporation (RXII) Updated Broker Price TargetsShare Trading Newsall 2 news articles »
05/20/16 12:04 PMRXI PHARMACEUTICALS CORP Financials -
05/19/16 08:58 PMAlpha One Assigns Impact Score Of 0 To RXI Pharmaceuticals Corporation (NASDAQ:RXII) - RealistInvestor.com - Alpha One Assigns Impact Score Of 0 To RXI Pharmaceuticals Corporation (NASDAQ:RXII)RealistInvestor.comAlpha One analyzed the various web articles published on RXI Pharmaceuticals Corporation (NASDAQ:RXII), and thereafter it gave company a daily sentiment score of 0.56. The entity designs algorithm based assessment to known stock sentiment on stock ...and more »
05/12/16 04:09 PMHC Stocks in Hub: CTI BioPharma Corp (CTIC), CytRx Corporation (CYTR), RXi Pharmaceuticals Corp (RXII) - share market updates (press release) - HC Stocks in Hub: CTI BioPharma Corp (CTIC), CytRx Corporation (CYTR), RXi Pharmaceuticals Corp (RXII)share market updates (press release)Shares of CTI BioPharma Corp (NASDAQ:CTIC) ended Wednesday session in red amid volatile trading. The shares closed down -0.016 points or -3.58% at $0.420 with 3.05 million shares getting traded. Post opening the session at $0.48, the shares hit an ...and more »
05/12/16 06:18 AMRXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -
05/12/16 06:07 AMQ1 2016 Rxi Pharmaceuticals Corp Earnings Release - After Market Close -
05/12/16 06:03 AMRXI PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report -
05/12/16 06:02 AMRXi Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Corporate Developments - [PR Newswire] - MARLBOROUGH, Mass., May 12, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address ...
05/10/16 05:55 AMRXi Pharmaceuticals Provides Strategic Update - [PR Newswire] - MARLBOROUGH, Mass., May 10, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today announced that it is in the process of exploring strategic options including a range of potential M&A and business development opportunities designed to enhance shareholder value. As part of this effort, RXi has engaged Griffin Securities, Inc. ("Griffin") for one of these transactions. "Following our recent reverse stock split and the full conversion of our preferred stock at the end of 2015, we have successfully reset the Company's capital structure and are now better positioned to execute on one or more strategic transactions that would significantly advance our Company," stated Dr. Geert Cauwenbergh, President and Chief Executive Officer of RXi.
05/05/16 04:19 PMLatest Analyst Ratings For RXI Pharmaceuticals Corporation (RXII) - Share Trading News - Latest Analyst Ratings For RXI Pharmaceuticals Corporation (RXII)Share Trading NewsRXI Pharmaceuticals Corporation has a 50 day moving average of 2.54 and a 200 day moving average of 3.30. The stock's market capitalization is 135.93M, it has a 52-week low of 2.00 and a 52-week high of 6.49. The share price of the company (RXII) was ...Could RXi Pharmaceuticals Corp See a Reversal After This Very Weak Session?B.O.D.Y Confidentialall 4 news articles »
05/04/16 03:44 PMRXI PHARMACEUTICALS CORP Files SEC form 8-K, Other Events -
05/04/16 06:02 AMRXi Pharmaceuticals to Present an Update on its Consumer Health Programs at the Society for Investigative Dermatology 75th Annual Meeting - [PR Newswire] - MARLBOROUGH, Mass., May 4, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it will present new data from the Company's consumer health development program, based on its proprietary self-delivering RNAi (sd-rxRNA®) technology, at the Society for Investigative Dermatology (SID) 75th Annual Meeting. The SID mission is to advance and promote the sciences relevant to skin health and disease through education, advocacy and scholarly exchange of scientific information. RXi's consumer health compounds are intended to affect the appearance of the skin. On Thursday, May 12, 2016, from 10:00 a.m. to 12:00 p.m. MST, data will be presented on the Company's ongoing work with its sd-rxRNA® compounds that target tyrosinase (TYR), a key enzyme in the synthesis of melanin.
05/03/16 06:12 AMRXi Pharmaceuticals and Thera Neuropharma Enter into an Exclusive License Agreement for RXi's Self-Delivering RNAi (sd-rxRNA®) Platform Targeting SOD1 to Develop Therapeutics for Neurodegenerative Diseases, such as ALS (Lou Gehrig's Disease - [PR Newswire] - MARLBOROUGH, Mass., May 3, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXi) (RXII) and privately-held Thera Neuropharma, Inc. (Thera) announced today that they have entered into an exclusive license agreement for RXi's novel and proprietary sd-rxRNA® platform to develop therapeutics for neurodegenerative diseases. Under the terms of the agreement, Thera will be responsible for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. The initial focus of the agreement will be on sd-rxRNA compounds targeting superoxide dismutase 1 (SOD1) for use in developing innovative treatments for amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease.
05/02/16 04:24 PMBroker Outlook For The Week Ahead: RXI Pharmaceuticals Corporation (RXII) - Share Trading News - Broker Outlook For The Week Ahead: RXI Pharmaceuticals Corporation (RXII)Share Trading NewsThey now have a USD 8 price target on the stock. The share price of RXI Pharmaceuticals Corporation (RXII) was up +2.30% during the last trading session, with a day high of 2.22. 26587 shares were traded on RXI Pharmaceuticals Corporation's last ...RXi Pharmaceuticals Secures European Patent for Novel RNAi PlatformPR Newswire (press release)RXI Pharmaceuticals Granted European Patent for RNAi Platform; Shares Unchanged in Pre Market (NASDAQ:RXII)Sonoran Weekly Reviewall 4 news articles »
05/02/16 06:02 AMRXi Pharmaceuticals Secures European Patent for Novel RNAi Platform - [PR Newswire] - MARLBOROUGH, Mass., May 2, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it has been granted a patent from the European Patent Office (EPO) for the composition of matter for its self-delivering RNAi platform (sd-rxRNA®). The Patent (EP 2 340 310 B1), titled "Reduced Size Self-Delivering RNAi Compounds" broadly covers the composition of RXi's sd-rxRNA platform and is not scheduled to expire until 2029. "We are pleased that our novel platform has been recognized with the granting of this patent by the European Patent Office," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals.
04/30/16 04:04 PMRXI Pharma (RXII) Announces New, Positive Data for RXI-109 in Late-Stage AMD - RXi Pharmaceuticals Corporation (NASDAQ: RXII) announced that the Company has generated new data demonstrating corneal delivery of a fluorescent analog of RXI-109, the Company's most advanced clinical compound, currently in human clinical trials for dermal ...
04/28/16 04:25 PMRXI Pharma (RXII) Announces New, Positive Data for RXI-109 in Late-Stage AMD - StreetInsider.com - RXI Pharma (RXII) Announces New, Positive Data for RXI-109 in Late-Stage AMDStreetInsider.comRXi Pharmaceuticals Corporation (NASDAQ: RXII) announced that the Company has generated new data demonstrating corneal delivery of a fluorescent analog of RXI-109, the Company's most advanced clinical compound, currently in human clinical trials ...and more »
04/28/16 06:02 AMRXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model - [PR Newswire] - MARLBOROUGH, Mass., April 28, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that ...
04/27/16 06:02 AMRXi Pharmaceuticals to Webcast First Quarter 2016 Financial Results on Thursday, May 12, 2016 - [PR Newswire] - MARLBOROUGH, Mass., April 27, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today announced that it will report its financial results for the first quarter ended March 31, 2016, and provide a business update on Thursday, May 12, 2016 after the close of the U.S. financial markets. The webcast link is available under the "Investors - Event Calendar" section of the Company's website, www.rxipharma.com. The event may also be accessed by dialing toll-free in the United States and Canada: +1 888-669-0684. RXi Pharmaceuticals Corporation (RXII) is a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant high-unmet medical needs. Building on the pioneering work of RXi's Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, our discovery and clinical development programs are based on our proprietary RNAi (sd-rxRNA®) platform and Samcyprone™, a topical immunomodulator.
04/26/16 06:02 AMRXi Pharmaceuticals Announces 'Biotech Spotlight' Presentation at the BioNetwork Partnering Summit - [PR Newswire] - MARLBOROUGH, Mass., April 26, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it will present at the BioNetwork Partnering Summit on May 3, 2016 at 9:15 a.m. EDT. The Company has secured a premier presentation slot providing a platform to present to the industry's senior business development executives and institutional investors. James Cardia, Ph.D., RXi's Director of Business Development and Intellectual Property, will present an overview of the Company's novel self-delivering RNAi (sd-rxRNA®) technology and the multiple business development and commercial opportunities available based on this proprietary platform.
04/26/16 03:13 AMCytRx: Ok Science, Bad Past, Unknown Future - On July 25, 2002, our former president and chief executive officer and board member through 2004 became a member of the board of directors of CytRx Corp. We also paid ... been as fantastic with Rxi Pharmaceuticals (NASDAQ:RXII) in which CytRx had a large ...
04/25/16 04:58 PMRXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference - PR Newswire (press release) - RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics ConferencePR Newswire (press release)MARLBOROUGH, Mass., April 25 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, ...and more »
04/25/16 06:02 AMRXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference - [PR Newswire] - MARLBOROUGH, Mass., April 25 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that ...
04/24/16 02:19 AMHow Analysts Feel About RXi Pharmaceuticals Corp After Today's Huge Decline? - The Post - How Analysts Feel About RXi Pharmaceuticals Corp After Today's Huge Decline?The PostThe stock of RXi Pharmaceuticals Corp (NASDAQ:RXII) is a huge mover today! The stock decreased 5.33% or $0.12 on April 22, hitting $2.13. About 113,870 shares traded hands or 188.22% up from the average. RXi Pharmaceuticals Corp (NASDAQ:RXII) ...Rxi Pharmaceuticals Corporation (NASDAQ:RXII) Shorted Shares Decreased By 9.71%B.O.D.Y Confidentialall 2 news articles »
04/23/16 02:37 AMRxi Pharmaceuticals Corporation (NASDAQ:RXII) Shorted Shares Decreased By 9.71% - B.O.D.Y Confidential - Rxi Pharmaceuticals Corporation (NASDAQ:RXII) Shorted Shares Decreased By 9.71%B.O.D.Y ConfidentialThe stock of Rxi Pharmaceuticals Corporation (NASDAQ:RXII) registered a decrease of 9.71% in short interest. RXII's total short interest was 2.02M shares in April as published by FINRA. Its down 9.71% from 2.24 million shares, reported previously.
04/22/16 09:31 PMRXI Pharmaceuticals Corporation (RXII) Updated Broker Price Targets - Share Trading News - RXI Pharmaceuticals Corporation (RXII) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of RXI Pharmaceuticals Corporation (RXII). The latest reports which are currently in issue on Friday 22nd of April state 0 analysts have a rating of “strong buy”, 0 ...Analyst Review: RXI Pharmaceuticals Corporation (RXII)Risers & Fallersall 2 news articles »
04/22/16 04:24 PMAnalyst Review: RXI Pharmaceuticals Corporation (RXII) - Risers & Fallers - Analyst Review: RXI Pharmaceuticals Corporation (RXII)Risers & FallersA number of investment brokers have recently updated their price targets on shares of RXI Pharmaceuticals Corporation (RXII). According to the latest broker reports outstanding on Friday 22nd of April, 0 analysts have a rating of “strong buy”, 0 ...RXI Pharmaceuticals Corporation (RXII) Updated Broker Price TargetsShare Trading Newsall 2 news articles »
04/21/16 09:27 PMRXI Pharmaceuticals Corporation (RXII) Updated Broker Ratings - Risers & Fallers - RXI Pharmaceuticals Corporation (RXII) Updated Broker RatingsRisers & FallersA number of investment brokers have recently updated their price targets on shares of RXI Pharmaceuticals Corporation (RXII). According to the latest broker reports outstanding on Thursday 21st of April, 0 analysts have a rating of “strong buy”, 0 ...RXi Pharma (NASDAQ: RXII) Fights For ListingScibility Mediaall 2 news articles »
04/21/16 04:22 PMRXi Pharmaceuticals gene therapy gets patent boost - RXi Pharmaceuticals Corp (NASDAQ:RXII) told investors it has fortified its patent portfolio for its novel RNAi gene therapies. The company said that it has received a notice of allowance, from the United States Patent and Trademark Office (USPTO ...
04/20/16 09:27 PMRXi Pharmaceuticals Corp (NASDAQ:RXII) Shows Some Momentum - Journal Transcript - Journal TranscriptRXi Pharmaceuticals Corp (NASDAQ:RXII) Shows Some MomentumJournal TranscriptDr. Geert Cauwenbergh, the CEO and President of RXi, said that they are delighted to have be given this Notice of Allowance. This patent protection for self-delivering RNAi technology strengthens their position to generate revenue and commercial ...Broker Roundup For RXI Pharmaceuticals Corporation (RXII)Share Trading Newsall 2 news articles »
04/20/16 04:21 PMBroker Roundup For RXI Pharmaceuticals Corporation (RXII) - Share Trading News - Journal TranscriptBroker Roundup For RXI Pharmaceuticals Corporation (RXII)Share Trading NewsThe share price of RXI Pharmaceuticals Corporation (RXII) was down -1.63% during the last trading session, with a day high of 2.55. 236636 shares were traded on RXI Pharmaceuticals Corporation's last session. The stock's 50 day moving average is 2.76 ...RXi Pharmaceuticals Corp (NASDAQ:RXII) Shows Some MomentumJournal Transcriptall 2 news articles »
04/20/16 02:41 AMRXI Pharma (RXII) Receives USPTO Notice of Allowance Related to RXI-109 - StreetInsider.com - Proactive Investors USA & CanadaRXI Pharma (RXII) Receives USPTO Notice of Allowance Related to RXI-109StreetInsider.comRXi Pharmaceuticals Corporation (NASDAQ: RXII) announced that it has received a Notice of Allowance, from the United States Patent and Trademark Office (USPTO), for both the composition of matter and methods of use for its self-delivering RNAi ...RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate ...PR Newswire (press release)RXI Pharmaceuticals Expands Patent Portfolio With Notice of Allowance for Composition of Lead Drug Candidate ...Sonoran Weekly ReviewRXi Pharmaceuticals gene therapy gets patent boostProactive Investors USA & Canadaall 5 news articles »
04/19/16 06:02 AMRXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109 - [PR Newswire] - MARLBOROUGH, Mass., April 19, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that ...
04/18/16 04:22 PMRXi Pharmaceuticals Corp (NASDAQ:RXII)'s Company Shares Decreased 10.34% After High Volatility - Business Standard Tribune - Wall Street 24RXi Pharmaceuticals Corp (NASDAQ:RXII)'s Company Shares Decreased 10.34% After High VolatilityBusiness Standard TribuneThe shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) decreased by 10.34% in the last 20 days and lost 2.62% in the past 5 trading sessions. RXi Pharmaceuticals Corp (NASDAQ:RXII) shares opened at $0.27 in the last session and had intraday high of ...AbbVie Inc (NYSE:ABBV) & RXi Pharmaceuticals (NASDAQ:RXII) Stocks to TrackWall Street 24RXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2016 Annual MeetingPR Newswire (press release)Investors Are Watching: Ford Motor Company (NYSE:F), Lennox International, Inc. (NYSE:LII), Natural Alternatives ...Benchmark Monitorall 4 news articles »
04/18/16 06:03 AMSplits Calendar: RXi Pharma splits before market open today (1:10 ratio) -
04/18/16 06:02 AMRXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2016 Annual Meeting - [PR Newswire] - MARLBOROUGH, Mass., April 18, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that ...
04/15/16 04:17 PMRXI Pharma (RXII) Announces 1-for-10 Reverse Stock Split - StreetInsider.com - RXI Pharma (RXII) Announces 1-for-10 Reverse Stock SplitStreetInsider.comRXi Pharmaceuticals Corporation (NASDAQ: RXII) today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on April 18, 2016, and shares of RXi ...Rxi Pharmaceuticals Corp (NASDAQ:RXII) Institutional Investor Sentiment TrendBusiness Standard TribuneRXi Pharma to reverse split stock 1:10 effective April 18Seeking Alphaall 3 news articles »
04/15/16 01:26 PMRXI PHARMACEUTICALS CORP Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Artic -
04/15/16 01:22 PM2:22 pm RXi Pharma announces 1:10 reverse split; to trade ex-split at the open April 18, 2016 -
About RXi Pharmaceuticals Corp

RXi Pharmaceuticals Corp logoRXi Pharmaceuticals Corporation is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs, primarily in the areas of dermatology and ophthalmology. The Company's development programs are based on its siRNA technology and immunotherapy agents. Its clinical development programs include self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring, and an immunodulating agent, Samcyprone, for the treatment of such disorders as alopecia areata, warts and cutaneous metastases of melanoma. In addition to these clinical programs, the Company has a pipeline of discovery and preclinical product candidates in its core therapeutic areas, as well as in other areas of interest.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RXII
  • CUSIP:
Key Metrics:
  • Previous Close: $2.90
  • 50 Day Moving Average: $2.18
  • 200 Day Moving Average: $2.80
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $18.95M
  • Current Quarter EPS Consensus Estimate: $-1.48 EPS
Additional Links:
RXi Pharmaceuticals Corp (NASDAQ:RXII) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha